Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer

OBJECTIVE: Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:ESMO Open
Hlavní autoři: Nishio, Makoto, Hida, Toyoaki, Atagi, Shinji, Sakai, Hiroshi, Nakagawa, Kazuhiko, Takahashi, Toshiaki, Nogami, Naoyuki, Saka, Hideo, Takenoyama, Mitsuhiro, Maemondo, Makoto, Ohe, Yuichiro, Nokihara, Hiroshi, Hirashima, Tomonori, Tanaka, Hiroshi, Fujita, Shiro, Takeda, Koji, Goto, Koichi, Satouchi, Miyako, Isobe, Hiroshi, Minato, Koichi, Sumiyoshi, Naoki, Tamura, Tomohide
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2017
Témata:
ESMO Asia paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5566979/
https://ncbi.nlm.nih.gov/pubmed/28861280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000108
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky